Antiplatelet drugs: which targets for which treatments?

Antiplatelet drugs: which targets for which treatments?

The current standard care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous intervention. In very high-risk patients, glycoprotein (GP) IIb/IIIa antagonists may also be used. Secondary prevention of ischemic events requires...

which city? which right? for which peoples?

0

Newer drugs which influence behavior.

732 M ANY chemicals affect the behavior of children in health and in disease. Often the precise mode of action of these is elusive. The effect of insulin in erasing coma from a diabetic child is better known to us than the method by which the insulin does so. When a chemical has a reproducible effect-either preventive or therapeutic-which is considered desirable, we use it. The therapeutic skep...

Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs.

OBJECTIVE Tissue factor (TF) is the main activator of the coagulation cascade occurring in physiologic and pathologic conditions. Recent data suggest that human platelets might contain TF that is possibly derived from leukocytes. In this study, we investigated whether intraplatelet TF can be exposed on the membrane by platelet agonists. The modulation of this process by antiplatelet drugs has b...

Which second line treatments after ESA failure?